Belvedere Trading
CUE icon

Belvedere Trading’s Cue Biopharma CUE Stock Holding History

Belvedere Trading’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-661
Closed -$178K – 498
2021
Q4 		$178K Buy
+661
New +$256K 0.01% 224
2021
Q2 		– Sell
-310
Closed -$113K – 364
2021
Q1 		$113K Buy
310
+191
+161% +$78.6K 0.01% 202
2020
Q4 		$45K Buy
+119
New +$47.5K ﹤0.01% 178

Other funds holding CUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belvedere Trading's CUE Position: Q1 2022 in Review

Belvedere Trading sold out of Cue Biopharma (CUE) in Q1 2022, closing a stake of 661 shares — an estimated $178K sold.

Belvedere Trading first reported a position in CUE in Q4 2020 and held it in 3 quarters. The position peaked at $178K in Q4 2021. 100 funds tracked by Wall St. Rank hold CUE as of Q1 2022.

  • Belvedere Trading reported no remaining Cue Biopharma position as of Q1 2022 after selling out during the quarter.
  • Belvedere Trading sold 661 Cue Biopharma shares in Q1 2022, an estimated $178K.
  • Belvedere Trading first reported a position in Cue Biopharma in Q4 2020 and held it in 3 quarters.
  • Belvedere Trading's Cue Biopharma position peaked at $178K in Q4 2021.
  • 100 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2022.

Based on Belvedere Trading's 13F filing for Q1 2022, filed 20 Apr 2022.